ASCO 2026 | Phase III MACE trial: metronomic chemotherapy after surgery in oral cavity squamous cell carcinoma
Nandini Menon, MBBS, MD, DNB, Tata Memorial Centre, Mumbai, India, discusses the results of a Phase III randomized controlled trial investigating metronomic adjunct chemotherapy (MACE) in locally advanced oral cavity squamous cell carcinoma post-surgery and adjuvant treatment, where patients received low-dose methotrexate and celecoxib. Dr Menon highlights that although the study did not meet statistical significance due to being underpowered, there was a numerical increase in overall survival with metronomic chemotherapy, particularly in high-risk subgroups, suggesting a potential signal that warrants further investigation. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
